Probiomed has been acquired by Sanfer
May 2022 — The shareholders of Probiomed S.A. de C.V. have sold the company to Laboratorios Sanfer.
Probiomed was founded in 1970 and is a vertically integrated developer, manufacturer and marketer of pharmaceutical and biopharmaceutical products. The company has three production plants and one of the most advanced R&D platforms in the region. The R&D team has 46 engineers who have developed and launched over 120 products, 14 of which were biopharmaceuticals.
Sanfer, with over 80 years of history, is one of the leading companies in the Mexican pharmaceutical market. It participates in more than 10 therapeutic areas, including infectiology, algology, cardiology, gastroenterology, central nervous system, metabolic syndrome, gynecology, urology, oncology, over-the-counter products and animal health products for all types of species.
Our role in the transaction
Oaklins’ team in Mexico acted as the financial advisor to Probiomed in the debt restructuring of US$120 million under Chapter 11 “Concurso Mercantil” in Mexico, as well as in the structuring of the acquisition by Sanfer, resulting in an equity injection of US$30 million.
Talk to the deal team
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Learn more